Nearly one in 10 Britons use or want weight-loss medication
A nationally representative survey estimates that millions of adults in Great Britain have already used GLP-1-based weight-loss medicines…
GLP-1RAs linked to lower risk of amputation in diabetes with PAD
The largest meta-analysis to date suggests GLP-1RAs may reduce major limb complications in people with type 2 diabetes…
GLP-1 exposure in pregnancy does not clearly raise major birth defect risk
Large-scale evidence offers cautious reassurance after inadvertent GLP-1 exposure in pregnancy, but unresolved risks and low-certainty data mean…
Simple blood test could identify the most effective obesity drug
A simple fasting blood test measuring two key incretin hormones could help match patients with severe obesity to…
Could GLP-1 drugs help breast cancer patients live longer?
A major real-world study links GLP-1 receptor agonists to improved survival and lower recurrence risk in women with…
GLP-1 drugs combined with surgery yield superior weight loss results
People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery…
A new tool that predicts obesity-related disease risk beyond BMI
A data-driven tool built from nearly 200,000 individuals reveals who is most likely to develop serious obesity-related diseases,…
GLP-1 drugs promise wider health benefits, but experts urge caution on use
As GLP-1 receptor agonists move beyond blood sugar and weight loss, a new review shows why clinicians must…
Study identifies epigenetic patterns affecting insulin and glucagon production in type 2 diabetes
Researchers at Lund University in Sweden have carried out the most detailed mapping to date of the epigenome…
Eli Lilly’s Retatrutide Shows Strong Weight Loss, Nears Diabetes Approval
Retatrutide’s Triple Action Targets Metabolism Eli Lilly’s retatrutide drug is making waves in the metabolic health field. It…
GLP-1 drugs cut heart and kidney risks in type 1 diabetes study
A major real-world analysis suggests GLP-1 receptor agonists could offer heart, kidney, and weight benefits in type 1…
Patients who stop GLP-1 drugs often restart or try alternatives
A large real-world study shows that patients who stop popular GLP-1–based weight-loss drugs often return to treatment or…